Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients

Phase 3CompletedNCT01119937

Novartis Pharmaceuticals211 enrolled

Overview

This is a 52-week, multi-center, randomized, open label, parallel group study to assess the long term safety and tolerability of once-daily NVA237, using tiotropium as an active control, in Japanese patients with moderate to severe chronic obstructive pulmonary disease (COPD) .

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

211

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

NVA237DRUG

50µg capsules for inhalation, delivered via a single dose dry powder inhaler (Concept 1®)

TiotropiumDRUG

18µg capsules for inhalation, delivered via HandiHaler®

Eligibility

Sex: ALLMin age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with moderate to severe stable COPD (Stage II or Stage III) according to the Gold Guideline 2008. * Current or ex-smokers who have a smoking history of at least 10 pack years. * Patients with a post-bronchodilator FEV1 ≥30% and \< 80% of the predicted normal, and postbronchodilator FEV1/FVC \< 0.7 at Visit 2 (day -7) Exclusion Criteria: * Pregnant women or nursing mothers or women of child-bearing potential not using an acceptable method of contraception * Patients requiring long term oxygen therapy * Patients who have had a lower respiratory tract infection within 6 weeks prior to Visit 1 * Patients with concomitant pulmonary disease * Patients with a history of asthma * Any patient with lung cancer or a history of lung cancer * Patients with a history of certain cardiovascular comorbid conditions * Patients with a known history and diagnosis of alpha-1 antitrypsin deficiency * Patients in the active phase of a supervised pulmonary rehabilitation program * Patients contraindicated for tiotropium or ipratropium treatment or who have shown an untoward reaction to inhaled anticholinergic agents * Other protocol-defined inclusion/exclusion criteria may apply

Locations (40)

Outcomes

Primary Outcomes

Number of Participants With Adverse Events, Serious Adverse Events or Death

Adverse events are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal lab finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgments of the investigators represent significant hazards.

Time frame: 52 weeks

Secondary Outcomes

Change in Pre-dose FEV1 From Baseline

Pre-dose FEV1 is defined as the average of the measurements at 45 and 15 minutes pre-dose.

Time frame: Weeks 12, 24, 36 and 52

Change in Pre-dose FVC From Baseline

Pre-dose FVC is defined as the average of the measurements at 45 and 15 minutes pre-dose.

Time frame: Weeks 12, 24, 36 and 52

Time From Randomization Until the Start of the First Moderate or Severe COPD Exacerbation

Moderate COPD exacerbations were defined as: worsening of 2 or more of the following major symptoms for at least 2 consecutive days - dyspnea, sputum volume and sputum purulence; OR a worsening of any 1 major symptom with any 1 of the following minor symptoms for at least 2 consecutive days - sore throat, colds, fever without other cause, increased cough or increased wheeze, requiring treatment with systemic glucocorticosteroids or antibiotics or both. Severe COPD exacerbations were defined as: conditions for Moderate COPD exacerbation and hospitalization was required. Participants who withdraw from the study and do not experience a moderate or severe exacerbation are censored at the date of withdrawal. Participants who complete the study and do not experience a moderate or severe exacerbation are censored at the completion visit date.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Novartis Investigative Site

Fukuoka, Fukuoka, Japan

Novartis Investigative Site

Iizuka, Fukuoka, Japan

Novartis Investigative Site

Kitakyushu, Fukuoka, Japan

Novartis Investigative Site

Kitakyushu, Fukuoka, Japan

Novartis Investigative Site

Kurume, Fukuoka, Japan

Novartis Investigative Site

Ōnojō, Fukuoka, Japan

Novartis Investigative Site

Yanagawa, Fukuoka, Japan

Novartis Investigative Site

Asahikawa, Hokkaido, Japan

Novartis Investigative Site

Obihiro, Hokkaido, Japan

Novartis Investigative Site

Sapporo, Hokkaido, Japan

...and 30 more locations

Time frame: 52 weeks

Number of Patients With Moderate or Severe COPD Exacerbations

Time frame: 52 weeks

Change in St. George Respiratory Questionnaire From Baseline

SGRQ is a health related quality of life questionnaire consisting of 51 items in three components: symptoms, activity, and impacts. The lowest possible value is zero and the highest 100. Higher values correspond to greater impairment in quality of life.

Time frame: Weeks 12, 24, 36, 52

Change From Baseline in Mean Daily Number of Puffs of Rescue Medication Over the Whole Treatment Period

Patients recorded rescue medication use in a paper patient diary. If a patient required the use of salbutamol as rescue medication due to an increase in COPD symptoms, the number of inhalations (puffs) taken was recorded in the patient diary.

Time frame: 52 weeks

Number of Patients With Newly Occurring or Worsening Clinically Notable Hematology Values at Any Timepoint Over the Whole Treatment Period

Clinically notable hematology values were: hemoglobin - male \<11.5g/dL, female \<9.5 g/dL; hematocrit - male \<37%, female \<32%; white cell count - \<2800µL or \>16000µL; platelets - \<7.5 10\*4/µL or \>70.0 10\*4/µL

Time frame: 52 weeks

Number of Patients With Newly Occurring or Worsening Clinically Notable Biochemistry Values at Any Timepoint Over the Whole Treatment Period

Clinically notable biochemistry values were: total protein - \<4.0 g/dL or \>9.5 g/dL; albumin \<2.5 g/dL; bilirubin (total) \>1.9 mg/dL; BUN \>27 mg/dL; creatinine \>1.99 mg/dL; AST \>3 x ULN U/L; ALT \>3 x ULN U/L; ALP \>3 x ULN U/L; y-GTP \>3 x ULN U/L; sodium \<125 mEq/L or \>160 mEq/L; potassium \<3.0 mEq/L or \>6.0 mEq/L; glucose \<51.0 mg/dL or \>180.0 mg/dL

Time frame: 52 weeks

Number of Patients With Newly Occurring or Worsening Clinically Notable Vital Signs Values at Any Timepoint Over the Whole Treatment Period

Clinically notable vital sign values were: pulse rate - low, \<40 bpm or \<=50 bpm and decrease from baseline \>=15bpm; pulse rate high, \>130 bpm or \>=120bpm and increase from baseline \>=15 bpm. Systolic blood pressure - low, \<75 mmHg or \<=90 mmHg and decrease from baseline \>=20 mmHg; high, \>200 mmHg or \>=180 mmHg and increase from baseline \>=20 mmHg. Diastolic blood pressure - low, \<40 mmHg or \<=50 mmHg and decrease from baseline \>=15 mmHg; high, \>115 mmHg or \>=105 mmHg and increase from baseline \>=15 mmHg.

Time frame: 52 weeks

Number of Patients With Notable Change From Baseline in Fridericia's QTc Values at Any Timepoint Over the Whole Treatment Period

Clinically notable change from baseline was and increase from baseline of 30 or greater milliseconds (ms).

Time frame: 52 weeks